Office probing for treatment of nasolacrimal duct obstruction in infants

详细信息    查看全文

• 作者：Aaron M. Miller ; MD ; MBA^a ; ^{pedignld3prob@jaeb.org" class="auth_mail} ; Danielle L. Chandler ; MSPH^b ; Michael X. Repka ; MD ; MBA^c ; Darren L. Hoover ; MD^d ; Katherine A. Lee ; MD ; PhD^e ; Michele Melia ; ScM^b ; Paul J. Rychwalski ; MD^f ; David I. Silbert ; MD^g ; on behalf of the Pediatric Eye Disease Investigator Group &lowast
• 刊名：Journal of American Association for Pediatric Ophthalmology and Strabismus
• 出版年：February, 2014
• 年：2014
• 卷：18
• 期：1
• 页码：26-30
• 全文大小：114 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferencesxml version="1.0" encoding="UTF-8"?>

Purpose

To determine whether demographic or clinical factors are associated with the outcome of office-based nasolacrimal duct probing for the treatment of congenital nasolacrimal duct obstruction (NLDO).

Methods

In two multicenter prospective studies, 384 eyes of 304 children aged 6 to <15 months with NLDO underwent a nasolacrimal duct probing performed in the office using topical anesthesia. Treatment success, defined as no clinical signs of NLDO (epiphora, increased tear lake, or mucous discharge) and no reoperation, was assessed 1 month after probing in one study and 6 months after probing in the other study. Data from both studies were pooled to evaluate associations between baseline characteristics and treatment success.

Results

Office probing was successful in 75% of eyes overall (95% CI, 70%-80%). The procedure was less successful in eyes of children with bilateral NLDO compared with unilateral NLDO (63% vs 80%; relative risk = 0.78 [95% CI, 0.66-0.92]) and in eyes that had 2 or 3 clinical signs of NLDO compared with one (71% vs 83%; relative risk = 0.88 [95% CI, 0.81-0.96]). Treatment success did not appear to be related to age, specific clinical signs of NLDO, prior treatment, or research study.

Conclusions

Performing nasolacrimal duct probing in the office successfully treats NLDO in the majority of cases in children aged 6 to <15 months. The success rate is lower with bilateral disease or when more than one clinical sign of NLDO is present.